-
EP4192819
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4192819
| EP4192819 - HETEROBIARYL COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 12.05.2023 Database last updated on 15.06.2024 | |
| Former | The international publication has been made Status updated on 11.02.2022 | ||
| Former | unknown Status updated on 22.09.2021 | Most recent event Tooltip | 13.10.2023 | Change: Validation states | published on 15.11.2023 [2023/46] | 13.10.2023 | Change - extension states | published on 15.11.2023 [2023/46] | Applicant(s) | For all designated states CHDI Foundation, Inc. c/o CHDI Management, Inc. 350 Seventh Avenue Suite 200 New York, NY 10001 / US | [2023/24] | Inventor(s) | 01 /
LIU, Longbin New York, New York 10001 / US | 02 /
DOMINGUEZ, Celia New York, New York 10001 / US | 03 /
CHEN, Xuemei New York, New York 10001 / US | 04 /
MANGETTE, John, E. New York, New York 10001 / US | [2023/24] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2023/24] | Application number, filing date | 21769835.6 | 05.08.2021 | [2023/24] | WO2021US44702 | Priority number, date | US202063062310P | 06.08.2020 Original published format: US 202063062310 P | [2023/24] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022031946 | Date: | 10.02.2022 | Language: | EN | [2022/06] | Type: | A1 Application with search report | No.: | EP4192819 | Date: | 14.06.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.02.2022 takes the place of the publication of the European patent application. | [2023/24] | Search report(s) | International search report - published on: | EP | 10.02.2022 | Classification | IPC: | C07D239/28, C07D401/06, C07D401/12, C07D401/14, C07D239/34, C07D239/36, C07D403/06, C07D403/12, C07D471/04, A61P25/28, C07B59/00 | [2023/24] | CPC: |
A61P25/28 (EP,IL);
C07D239/28 (EP,IL,KR,US);
A61K51/0459 (IL,KR,US);
C07B59/002 (EP,IL,KR);
C07D239/34 (EP,IL);
C07D239/36 (EP,IL);
C07D401/12 (EP,IL,KR,US);
C07D401/14 (EP,IL,KR,US);
C07D403/06 (EP,IL,KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/24] | Title | German: | HETEROBIARYLVERBINDUNGEN UND ABBILDUNGSMITTEL ZUR ABBILDUNG VON HUNTINGTINPROTEIN | [2023/24] | English: | HETEROBIARYL COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | [2023/24] | French: | COMPOSÉS HÉTÉROBIARYLES ET AGENTS D'IMAGERIE POUR L'IMAGERIE DE LA PROTÉINE HUNTINGTINE | [2023/24] | Entry into regional phase | 03.03.2023 | National basic fee paid | 03.03.2023 | Designation fee(s) paid | 03.03.2023 | Examination fee paid | Examination procedure | 03.03.2023 | Examination requested [2023/24] | 03.03.2023 | Date on which the examining division has become responsible | 20.09.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 28.08.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]WO2010137351 (RAQUALIA PHARMA INC [JP], et al) [I] 1,3,4,13-21,25,28-31,40,41,45 * compound of Example 118 on page 93; paragraph [0090]; claim 1 *; | [XI]WO2013033068 (COURTNEY STEPHEN MARTIN [GB], et al) [X] 2-4,15,19-22,24,27 * 1st and last but one compound on page 78, 1st on page 79; last but one compound on page 107, last compound on page 107 (5-oxo-pyrrolidin-3-yl), last compound on page 109; paragraphs [0114] , [0116] , [0165]; claims 1,31-35 * [I] 1-4,13-31; | [XI]WO2014049488 (PFIZER [US]) [X] 2,3,8,13,17,21-23,25,26 * generic formula (I) on page 2; compounds 100 and 102 on page 155, 108 on page 157, 110 and 111 on page 158, 115 on page 160, 124 on page 163; page 61, lines 12-32 * [I] 28,29; | [A]WO2016033445 (CHDI FOUNDATION INC [US], et al) [A] 1-45* compounds of examples;; claims 1,49-60 * | by applicant | - FOSTER, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., (19840000), vol. 5, no. 12, doi:10.1016/0165-6147(84)90534-0, pages 524 - 527, XP025943358 DOI: http://dx.doi.org/10.1016/0165-6147(84)90534-0 | - T. HIGUCHIV. STELLA, "Pro-drugs as Novel Delivery Systems", A.C.S. Symposium Series, vol. 14 | - MILLER et al., Angewandte Chemie International Edition, (20080000), vol. 47, pages 8998 - 9033 | - JACOBSON, O. et al., Bioconjugate Chem., (20150000), vol. 26, pages 1 - 18 | - DENG, X. et al., Angewandte Chemie International Edition, (20190000), vol. 58, no. 9, pages 2580 - 2605 | - FIESERFIESER, Reagents for Organic Synthesis, John Wiley, and Sons, (19910000), vol. 1-40 | - Larock's Comprehensive Organic Transformations, Elsevier Science Publishers, (19890000), vol. 1-5 | - SCHERZINGER et al., Cell, (19970808), vol. 90, pages 549 - 558 |